Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 683.0K
Operating Income -48.7M -7,123.13%
Net Income -45.4M -6,651.68%

Balance Sheet Metrics

Total Assets 97.2M
Total Liabilities 14.2M
Shareholders Equity 82.9M
Debt to Equity 0.17

Cash Flow Metrics

Operating Cash Flow -39.6M
Free Cash Flow -37.8M

Revenue & Profitability Trend

Cardiff Oncology Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 683.0K 488.0K 386.0K 359.0K 366.0K
Cost of Goods Sold - - - - -
Gross Profit - - - - -
Operating Expenses 49.3M 45.9M 40.3M 29.2M 19.5M
Operating Income -48.7M -45.4M -39.9M -28.9M -19.1M
Pre-tax Income -45.4M -41.4M -38.7M -28.3M -19.3M
Income Tax - - - - -
Net Income -45.4M -41.4M -38.7M -28.3M -19.3M
EPS (Diluted) - -$0.93 -$0.89 -$0.73 -$1.08

Income Statement Trend

Cardiff Oncology Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 95.1M 77.4M 111.3M 146.1M 133.4M
Non-Current Assets 2.1M 4.2M 4.9M 3.4M 1.4M
Total Assets 97.2M 81.6M 116.2M 149.5M 134.7M
Liabilities
Current Liabilities 13.4M 10.4M 7.8M 6.6M 6.1M
Non-Current Liabilities 813.0K 1.5M 2.0M 2.6M 450.0K
Total Liabilities 14.2M 11.9M 9.8M 9.1M 6.6M
Equity
Total Shareholders Equity 82.9M 69.7M 106.3M 140.4M 128.2M

Balance Sheet Composition

Cardiff Oncology Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -45.4M -41.4M -38.7M -28.3M -19.3M
Operating Cash Flow -39.6M -36.0M -35.4M -23.0M -16.5M
Investing Activities
Capital Expenditures - - - - -
Investing Cash Flow 13.8M 36.8M 39.2M -131.2M 0
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 53.4M - 0 34.2M 112.3M
Free Cash Flow -37.8M -31.5M -34.8M -23.2M -16.5M

Cash Flow Trend

Cardiff Oncology Key Financial Ratios

Valuation Ratios

Forward P/E -3.13
Price to Book 2.97
Price to Sales 358.13
PEG Ratio -3.13

Profitability Ratios

Profit Margin 0.00%
Operating Margin -13,194.50%
Return on Equity -74.15%
Return on Assets -41.00%

Financial Health

Current Ratio 6.22
Debt to Equity 1.91
Beta 1.56

Per Share Data

EPS (TTM) -$0.93
Book Value per Share $1.07
Revenue per Share $0.01

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
crdf 210.2M - 2.97 -74.15% 0.00% 1.91
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Alpha Tau Medical 245.6M - 3.63 -47.95% 0.00% 21.83
Cartesian 250.0M 1.81 -12.32 1,138.25% -112.11% -0.65
Foghorn Therapeutics 272.6M - -5.07 190.26% 0.00% -0.57

Financial data is updated regularly. All figures are in the company's reporting currency.